It’s been revealed that an experimental drug that is able to remove a substance called amyloid from the brain seems to be slowing down Alzheimer’s disease. Check out the latest reports about all this below.
Alzheimer’s drug shows promising results
The drug is called lecanemab, and it has been able to reduce the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer’s. This is what scientists reported at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco.
The study was published simultaneously in The New England Journal of Medicine.
People who got infusions of lecanemab scored about half a point better on a zero-to-18-point scale of mental functioning, a slight but statistically significant difference.
The results are “real and robust.” This is according to Dr. Christopher van Dyck, who directs the Yale Alzheimer’s Disease Research Center and presented an overview of the study at the meeting.
But Dr. Madhav Thambisetty of the National Institute on Aging, who was not involved in the study, called the results “a very small effect.”
“It’s very unlikely that these differences are going to be noticeable by individual patients in their everyday lives,” Thambisetty says.
We suggest that you check out the complete original article in order to learn more details about all this.
A new mathematical model for Alzheimer’s disease is out
It’s been revealed that experts have used a mathematical model to reveal how toxic proteins cluster together inside the brain during the early stages of Alzheimer’s.
The researchers from the University of York’s School of Physics, Engineering, and Technology say the discovery could have important implications for future treatments.
The study shows the fact that a major class of proteins implicated in Alzheimer’s disease condense into objects that resemble liquid droplets. This is before forming clusters that impact normal brain activity. Check out our previous article in order to learn more details about the issue.